Chronic Inflammatory Demyelinating Polyradiculo-neuropathy Clinical Trials
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare, immune-mediated neurological disorder where there is inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) of the nerve fibers. When the myelin sheath is damaged, nerve signals slow or become blocked, leading to progressive or relapsing muscle weakness, sensory changes, and impaired coordination.
CIDP can affect people of all ages, though it is more commonly diagnosed in adults, and its presentation varies widely from person to person. Some individuals experience a steadily progressive course, while others have periods of symptom worsening followed by partial recovery. Although current treatments such as immunoglobulin therapy, corticosteroids, and plasma exchange can be effective for many patients, not everyone responds adequately, and long-term therapy may bring significant burdens.
Clinical trials are essential to advancing care for people living with CIDP. Through clinical research, investigators evaluate new therapies and innovative treatment strategies. Participation in clinical trials may offer eligible patients access to emerging therapies while contributing to medical knowledge that can help shape future standards of care for CIDP.
At the Neurology Rare Disease Center, we are dedicated to advancing neurological care through active involvement in clinical research and compassionate, patient-centered support. Our experienced team works closely with individuals and families to explain available CIDP clinical trials, review eligibility criteria, and guide participants throughout the research journey with transparency and care. We encourage you to explore the clinical trial opportunities available at our center and learn more about how these studies work.
NCT06747351
A study to compare TAK-881 and HYQVIA in adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT07027111
Safety, tolerability, and efficacy of NVG-2089 in participants with CIDP
NCT06858579
A study to evaluate the efficacy and safety of DNTH103 in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Contact
Phone: (972) 982-7411
FAX: (972) 982-7610
Email: newpatient@neuromdcenter.com
Business Hours:
Monday – Friday
9AM- 5PM By Appointment Only
1651 Justin Rd.
Flower Mound, TX 75028
Content, including images, displayed on this website is protected by copyright laws.
Downloading, republication, retransmission or reproduction of content on this website is strictly prohibited. © NeuroMD. All Rights Reserved.